Serum Fibroblast Growth Factor 1 is Associated with the Decreased Risk of Obesity in Human

Exp Clin Endocrinol Diabetes. 2017 May;125(5):322-326. doi: 10.1055/s-0043-104532. Epub 2017 Mar 16.

Abstract

As a transducer of PPARγ signaling, recent evidence supports that fibroblast growth factor 1 (FGF1) mediates adipose tissue remodeling and insulin sensitivity. This study is to assess the role of serum FGF1 in obesity. A hospital-based case-control study of 154 subjects was conducted. Serum level of FGF1 was measured by enzyme-linked immunosorbent assay. The serum level of FGF1 in the lean (119.0 [103.1-146.1] pg/ml) was higher than it in the subjects with overweight/obesity (111.9 [80.3-127.4] pg/ml, P=0.009). Binary logistic regression models found a reverse association between serum FGF1 level and the risk of overweight/obesity (adjusted odds ratio=0.990, 95% confidence interval [0.981-0.998], P=0.019). Furthermore, serum FGF1 reversely correlated with body mass index (r=-0.176, P=0.029), systolic blood pressure (r=-0.224, P=0.005), diastolic blood pressure (r=-0.185, P=0.022) and triglycerides (r=-0.162, P=0.044). Multiple stepwise linear regression analysis found serum level of FGF1 was dependent on anti-diabetic drugs, hemoglobin A1C, body mass index and sex. Serum level of FGF1 is associated with the decreased risk of obesity in human.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Body Mass Index
  • Case-Control Studies
  • Female
  • Fibroblast Growth Factor 1 / blood*
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Male
  • Middle Aged
  • Obesity / blood*
  • Obesity / drug therapy
  • Risk Factors
  • Sex Factors

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • hemoglobin A1c protein, human
  • Fibroblast Growth Factor 1